To address this shortcoming, the Freedman group recently used an established nephron organoid model and determined that AV457, an mTORC1-selective inhibitor, has a significantly better safety profile than everolimus, a non-selective mTOR inhibitor, while showing comparable efficacy at slowing cyst growth [131]. This evidence concerns the gene MTOR and cyst.